![\"\"](\"https:\/\/www.eyedeal.com\/wp-content\/uploads\/2025\/04\/facced21d36b08268d9ee48973c7871-scaled.jpg\")
<\/p>\nOn the morning of April 26, the 51st Annual Meeting of the American Society of Cataract and Refractive Surgery (ASCRS) hosted its \u201cIntraocular Lens (IOL) Design and Characteristics\u201d sub-forum as scheduled. Renowned international ophthalmologist Professor Guy Kleinmann delivered an academic presentation titled “Biocompatibility Evaluation of a Novel Intraocular Lens Material”. He released the animal trial results of the next-generation Eyedeal\u00ae cross-linked polyisobutylene (xPIB) intraocular lens developed by Xi\u2019an Eyedeal Medical Technology Co., Ltd., providing a detailed assessment of the product’s exceptional biocompatibility features.<\/p>\n
<\/p>\n
The study conducted preclinical biocompatibility assessments through IOL implantation in rabbit eyes. Results showed that the Eyedeal\u00ae xPIB IOL demonstrated no significant differences in tissue response of the uveal tract and capsular bag compared to the control group using the current industry-standard material\u2014hydrophobic acrylic AcrySof\u00ae SA60AT (Alcon, Fort Worth, USA). Moreover, the Eyedeal\u00ae xPIB IOL showed a lower incidence of posterior capsular opacification (PCO) and Soemmerring\u2019s ring formation, highlighting its excellent overall biocompatibility.<\/p>\n
![\"\"](\"https:\/\/www.eyedeal.com\/wp-content\/uploads\/2025\/04\/c52240a22c5f06bfb2da0bdada24710-scaled.jpg\")
<\/p>\n
“Whether at one week or six weeks post-operation, both the Eyedeal\u00ae xPIB test group and the control group exhibited inflammatory responses within acceptable ranges, with no significant differences observed between them,” noted Professor Guy Kleinmann. He emphasized that, in rabbit models, a six-week period corresponds to a human postoperative response cycle of approximately three to five years. Throughout the observation period, the Eyedeal\u00ae xPIB IOL demonstrated remarkable stability in both inflammation control and capsular bag condition.<\/p>\n
About Professor Guy Kleinmann<\/strong><\/p>\n Dr. Guy Kleinmann, MD, graduated from the John A. Moran Eye Center at the University of Utah and currently serves as the Head of the Cataract Division at Kaplan Medical Center in Israel. His primary areas of research include the retina, glaucoma, and cataract.<\/p>\n He has made numerous contributions to the field of ophthalmology, including the study of square-edge IOL designs to prevent posterior capsule opacification and the management of ocular complications in type 1 diabetes, such as diabetic retinopathy. Professor Kleinmann has an H-index of 18, with 74 published papers and a total of 1,002 citations. He is a member of several prestigious professional organizations, including the Association for Research in Vision and Ophthalmology (ARVO), the American Society of Cataract and Refractive Surgery (ASCRS), the American Academy of Ophthalmology (AAO), and the Israel Ophthalmological Society.<\/p>\n","protected":false},"excerpt":{"rendered":" On the morning of April 26, the 51st Annual Meeting of the American Society of Cataract and Refractive Surgery (ASCRS) […]<\/p>\n","protected":false},"author":2,"featured_media":107841,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[93],"tags":[],"yoast_head":"\n![\"\"](\"https:\/\/www.eyedeal.com\/wp-content\/uploads\/2025\/04\/19105dd62f5a2611ac33d72d80c9c28-scaled.jpg\")
<\/strong><\/p>\n![\"\"](\"https:\/\/www.eyedeal.com\/wp-content\/uploads\/2025\/04\/1e5812e8e050b2e964a9dfe00b859ed.png\")
<\/p>\n